

# Company Presentation

## Forward – Looking Statement

*This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements may be identified by their use of terms or phrases such as "expects," "estimates," "projects," "believes," "anticipates," "plans," "intends," and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. For example, the Company (i) may be unable to continue its efforts on particular products due to future laboratory results, (ii) may be unable to obtain needed additional capital on acceptable terms, if at all, or meet its financial forecasts, (iii) may be unable to maintain, retain and develop its intellectual property, (iv) must address regulatory, competitive and marketing challenges in the course of developing its products. These and other risks are described elsewhere in this presentation and in our reports filed with the Securities and Exchange Commission, including our Form 10-K filed March 30, 2010, as subsequently amended. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.*

## Repair, don't Replace

**MiMedx Group, Inc.**, (OTCBB: MDXG) is an integrated developer, manufacturer, and marketer of patent protected biomaterial-based products. Our philosophy is to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures.

- MiMedx Group was formed through the combination of two early stage medical device companies, MiMedx, Inc. and SpineMedica Corp and in February 2008 the Company went public
- MiMedx Group holds exclusive rights to 8 issued and over 25 pending U.S. and foreign patent applications
- In 2009, MiMedx Group transitioned from a pre-revenue, development-focused concern to a revenue producing operating company focused on sales growth and profitability
- In 2009, MiMedx Group restructured the management team with the addition of several experienced and proven healthcare executives

## Board of Directors

Parker H. "Pete" Petit, Chairman

## Management Team

Parker H. "Pete" Petit	CEO
William C. Taylor	President & COO
Rebecca J.C. Brown, PhD	EVP, Product Development
Michael W. Carlton	EVP, Sales & Marketing
Don Fetterolf, MD, MBA	VP, Medical Affairs
William Jackson	VP, QA/RA
Tom J. Koob, PhD	Chief Scientific Officer
Thornton Kuntz	VP, HR & Administration
Roberta McCaw	VP & General Counsel
Michael J. Senken	VP & CFO

## Board of Directors

### **Parker H. (Pete) Petit — Chairman**

- Former Chairman and CEO of Matria Healthcare which was sold to Inverness Medical Innovations in May, 2008
- Matria Healthcare was a former subsidiary of Healthdyne, which Mr. Petit founded in 1970
- Served as Chairman and CEO of Healthdyne and some of its publicly traded subsidiaries after Healthdyne became a publicly traded company in 1981
- For further information, see [www.thepetitgroup.com](http://www.thepetitgroup.com)

### **Joseph G. Bleser**

- Experienced Healthcare Exec, CFO, Board member, Audit Chair
- Over 20 years as CFO of Public Healthcare & Technology companies
- Companies include: HBO, Healthdyne Information Enterprises, Allegiant Physician Svcs, Healthcare.com, Transcend Services
- BOD: Transcend Services (NASDAQ: TRCR), Matria Healthcare
- Licensed CPA with 10 yrs public accounting for international firm

### **Terry Dewberry**

- Experienced Healthcare Exec, Board member, Audit Chair
- Previously Director of Respironics, and Matria Healthcare
- Currently on Board of DrTango, a private multicultural communications and health management company
- Previously, Director, Vice Chairman, President and COO, and CFO of Healthdyne, 1981 – 1996
- Experience buy & sell side Corp M&A, transactions up to \$5 billion

### **Kurt Eichler**

- Serves as an EVP of LCOR Incorporated, a real estate investment and development company, in charge of operations in the metropolitan New York region
- Formerly in the Real Estate Debt and Equity Finance Group of Merrill Lynch, Hubbard
- Member of the Board of Governors, Real Estate Board of NY

### **Steve Gorlin – Vice Chairman**

- Founder of MiMedx Group, Inc.
- Founder of several biotechnology/pharmaceutical companies, including Hycor Biomedical, Theragenics (NYSE:TGX), CytRx (Nasdaq:CYTR), Medicis Pharmaceutical (NYSE:MRX), EntreMed (Nasdaq:ENMD), Surgi-Vision, DARA BioSciences, (Nasdaq:DARA), SpineMedica and Medivation (Nasdaq: MDVN)

### **Bruce Hack**

- Experienced Executive and leader in the multi-billion dollar global entertainment industry
- Former: Vice Chairman, Activision Blizzard; CEO, Vivendi Games; Vice Chairman, Universal Music Group; CFO, Universal Studios; CFO, Tropicana
- Founder, BLH Ventures
- Board member at Technicolor and iSuppli
- Education: MBA, University of Chicago, BA, Cornell University

### **Charles Koob**

- Successful M&A, Anti-trust, Corporate attorney at Simpson Thatcher and Bartlett
- Experience includes the defense of Appleton Papers, representation of Virgin Atlantic Airways, and the representation of a special committee of Archer Daniels Midland in a federal grand jury investigation of price-fixing

### **Larry Papasan**

- Venture Partner at MB Venture Partners
- Former President of Smith & Nephew Orthopedics
- Chairman at BioMimetic Therapeutics (Nasdaq:BMTI), Board Member at Memphis Biotech Group and Plough Foundation
- Chairman at Lebonheur Children's Hospital Foundation, Pres. of the Board at the Biblical Resource Center & Museum

### **Kreamer Rooke**

- Initial investor in MiMedx
- Advised on the acquisition of SpineMedica Corp.
- Former Investment Banking Analyst in the Global Healthcare Group of Collins Stewart, Inc.
- Graduate of the University of Pennsylvania: B.A. in Economics

## Strategic and Tactical Goals

### STRATEGIC

- Create a high growth and profitable biomaterials company from MiMedx Group's diverse intellectual property,
- Focus on technologies that can augment the repair, when possible, rather than replacing traumatized but otherwise healthy tissues and structures

### TACTICAL

- Capitalize on our intellectual property through internal product development as well as strategic partnerships
- Develop a network of independent sales representative network as the Company's distribution outlet in the United States
- Develop network of distributor partners in International markets
- Carefully choose a select number of larger orthopedic device manufacturers as joint product development partners who could also serve as distribution outlets
- Over time, add direct sales personnel to supplement the independent sales rep groups
- Keep management structure, controls and processes maturing ahead of the revenue growth profile
- Maintain excellent Wall Street rapport with analysts and brokerage houses

## MiMedx Group Physician Advisory Board (PAB)


James Andrews, MD	Alabama Sports Medicine Center, Birmingham, AL The Andrews-Paulos Institute, Gulf Breeze, FL
Randal Betz, MD	Shriners Hospital for Children, Philadelphia, PA
Martin Boyer, MD	Washington University School of Medicine, St. Louis, MO
Neal ElAttrache, MD	Kerlan Jobe Orthopedics Center, Los Angeles, CA
Glenn Gaston, MD	OrthoCarolina, Charlotte, NC
Gary Lourie, MD	Hand & Upper Extremity Center of Georgia, Alpharetta, GA
Lonnie Paulos, MD	The Andrews-Paulos Institute, Gulf Breeze, FL

*MiMedx also has Consulting Agreements with over 25 Key Opinion Leaders (KOLs) who assist on various projects in development*

# CollaFix

## CollaFix™

Collagen Technology with Exceptional Mechanical Performance  
and Biocompatibility for Connective Tissue Repair



## MiMedx Collagen: A Biomaterial Scaffold

MiMedx's collagen-based biomaterial technology, CollaFix™, acts as a platform or scaffold on which a patient's tissue grows during the healing process in order to achieve *healthy* tissue reconstruction without significant scarring.

While the patient's own cells are fabricating their own natural structure, CollaFix™ provides structural integrity and promotes better and faster healing. It is eventually absorbed, being replaced by newly formed, competent, healthy tissue rather than scar tissue.

CollaFix™ is intended to facilitate the repair by:

- Providing mechanical integrity during the healing process
- Biodegrading and being absorbed by the surrounding tissue without insult or future surgical intervention

NOTE: CollaFix™ products are not yet cleared for use and therefore are not available for sale

## CollaFix™ Product Characteristics

- Collagen is cross-linked using a proprietary and patented process
- Although intended only to augment soft tissue during repair, our collagen fibers are stronger than human tendons and ligaments
- Approximately same stiffness as human tendons and ligaments
- Forms a scaffold when implanted which allows for cell in-growth
- Biological—entirely organic materials, no synthetics
- Biodegradable—products are absorbed by the body during and after healing
- Manufactured as continuous fibers

## CollaFix™

### Potential Uses & Product Opportunities

Products embodying our collagen fiber technology for which we may seek regulatory clearances or approvals include:

- Orthopedic soft tissue augmentation and repair—tendons and ligaments
  - Repair for shoulder & rotator cuff, hand & elbow, knee, hip
  - Repair for foot and ankle—posterior tibial, peroneal, extensor and lateral tendons
  - Tubes for anchoring bone
- General surgery & wound care
  - Patches for wound healing to cover and protect (Diabetic foot ulcers, plantar soft tissue augmentation, etc.)
  - Sutures
  - Hernia patch
- Gynecological repair and organ support
  - Urethral slings, vaginal prolapse repair
- Neurological surgery
  - Nerve guides
- Plastic and reconstructive surgery
  - Soft tissue support, cranial maxillofacial reconstruction

## CollaFix™ Competition\*

### Tendon Protectors

- TenoGlide™ by Integra Life Sciences and TenoMend™ by Collagen Matrix: collagen wraps for protection of repaired tendons

### Tendon Augmentation or Repair Devices

- OrthAdapt® by Synovis/Pegasus: a collagen soft tissue scaffold in the form of a patch for reinforcement of rotator cuff and Achilles tendon repair
- GraftJacket® by Wright Medical: a collagen patch used for connective tissue repair and wound management
- FiberTape™ and FiberWire® by Arthrex: synthetic materials for reattaching all severed tendons and ligaments

\* Products that are competitive to some of the collagen fiber products for which we may seek regulatory clearance or approvals

## CollaFix™

### Advantages over Competition

Potential advantages of products manufactured from our collagen fibers over TenoGlide and TenoMend:

- Our products will also supply protection to the repair site
- Our products will go beyond simple repair protection by augmenting the repair

Potential advantages of products manufactured from our collagen fibers over GraftJacket, OrthAdapt, and FiberWire:

- Scalability: we can target fiber geometries to match the anatomy, GraftJacket and OrthAdapt are only offered as a patch
- Biologic: FiberWire is made of polyester, a synthetic material that can cause inflammation and is a permanent implant
- Stiffness: we can match native tissue stiffness, independent of implant size
- Strength: depending on size, 5x to 10x stronger than GraftJacket or OrthAdapt
- Biocompatible: novel cross-linking technology has no associated inflammatory response while degrading

## CollaFix™ Proprietary Technology

Patent No. 6,565,960 – A broad cross-linking process patent protects the technology  
Patent No. 6,821,530 – A related polymer composite patent

*Our collagen-fiber cross-linking patent is strong and broad: no competitor has a collagen fiber as strong, stiff, expandable, scalable, biocompatible and biomimetic, from a biological source.*

In addition to the basic technology patent and applications, the Company has filed and expects to continue filing patent applications for specific product configurations and uses. An additional 10 patents are pending as of the date of this report relating to the base technologies.


## CollaFix™ Product Configurations




Cables



Tubes




Patches




Knits

## CollaFix™ Superior Strength Versus Competitors



Individual values taken from published & Company literature


## CollaFix™ Strength Comparison to Native Tissue



\*Device strength can be tailored to match that of tendons and ligaments

Data from published & Company literature

## CollaFix™ Stiffness Comparison to Native Tissue




Stiffness mimics that of human tendons and ligaments

# HydroFix

## HydroFix™

### Durable, Biocompatible Hydrogel Technology

- Durable hydrogel products have numerous opportunities with initial product design focus on sheet applications
- Sheets provide the broadest initial market opportunities
- The first products on the market are HydroFix™ Vaso Shield in the U.S. and HydroFix™ Spine Shield in Europe, both of which have specific indications for use in anterior vertebral surgery



HydroFix™

## HydroFix™ Product Characteristics

- Silicone-like material with properties that can be tailored
- A durable hydrogel compound made of polyvinyl alcohol
- Prohibits cellular attachment or in-growth
- Patented and proprietary manufacturing processes
- Biocompatible
- Durable

## HydroFix™

### Potential Uses & Product Opportunities

Products embodying our hydrogel technology for which we may seek regulatory clearances or approvals include:

- Orthopedic Spine Repair
- Posterior vertebral surgery
- Cardiovascular and open heart surgery
- General surgery
- Hernia repair
- Plastic and reconstructive surgery
- Obstetrics & gynecological surgery
- Foot and Ankle cushioning device

## HydroFix™ Competition

### Preclude® Vessel Guard by W.L. Gore

- Only significant direct competitor
- Similar FDA indication to Vaso Shield
- Product is opaque
- Made of ePTFE (expanded-PolyTetraFloroEthylene)

### Septrafilm® by Genzyme

- FDA indication to reduce post-operative adhesions in open abdominal surgery
- Resorbs over time

### Interceed® by Ethicon/J&J

- FDA indication for gynecological use
- Acts as a barrier following surgery
- Resorbs over time

## HydroFix™

### Advantages over Competition

#### Potential advantages of HydroFix™ over Preclude Vessel Guard:

- Translucent
  - Surgeon can see through implant
  - Makes suturing easier
  - Makes implanting faster
  - Makes using safer
- MRI—can be visible on MRI, Preclude is not
- Thickness—easier to handle and does not fold over on itself
- Thickness—easier to feel edges and find during revision surgery


#### Potential advantages over Interceed and Seprafilm:

- Provides permanent and predictable protection
- Interceed and Seprafilm resorb
- HydroFix™ has specific indications for use in vertebral surgery

## HydroFix™ Proprietary Technology

### Durable Viscoelastic Polymer

- Owned and Licensed IP for products and manufacturing
  - 6 Issued, over 20 pending patents securing technology—US & Foreign
  - Material texture is similar to silicone without associated negative properties, such as silicone wear debris, biocompatibility issues
- Mimics properties of human tissue
- Biocompatible & highly durable
- Economical to produce
- Wide variety of proprietary manufacturing methods
- Easily integrated with other materials
- Proven pre-clinical & clinical performance
  - Knee Cartilage (EU) & Nerve Cuff (US)




Hydrogel devices have been used in the knee and foot over the past decade

## HydroFix™


HydroFix™ Spine Shield is CE Marked  
(European Clearance)

HydroFix™ Vaso Shield is FDA 510(k) Cleared

- Can be visible on MRI
- Sutured into place



HydroFix  
VASO SHIELD



HydroFix™ being implanted



First implant procedure

# Conclusion